Molecular pathogenesis and therapy for systemic histiocytic neoplasms
Official title: Molecular Pathogenesis and Therapy of Systemic Histiocytic Neoplasms
Funded at Sloan-Kettering Inst Can Research · NIH-11224806 · Data updated 2026-11-12
This grant focuses on understanding and treating disorders like LCH, ECD, JXG, and RDD that involve abnormal MAPK signaling and BRAFV600E or related mutations.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2026 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $550,806 |
| NIH project number | 4R37CA259260-06 |
| Project ID | NIH-11224806 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults (and older adolescents) with histiocytic neoplasms or related MAPK pathway alterations.
✕Less likely to help
Patients without BRAFV600E or MEK/BRAF pathway alterations may have limited benefit from these specific targeted approaches.
What this research studies
Histiocytic neoplasms are clonal diseases of immune cells that often carry MAPK pathway mutations. The project builds on prior findings that BRAFV600E mutations respond to BRAF inhibitors and that blood-based mutant DNA can track treatment response. It will explore genomic alterations in BRAFV600E-wildtype cases and assess MEK inhibitors as treatment options where BRAF inhibition is less effective. The work aims to link molecular markers with therapy to guide personalized care for patients with these conditions.
Why it matters
Potential benefit: Patients may receive more precise, mutation-guided therapies and better monitoring of response through blood biomarkers.
How similar studies have gone: Previous work showed BRAF inhibitors can be effective in BRAFV600E-mutant disease and cfDNA markers reflect response, supporting this line of investigation.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Diamond, Eli Lous — Sloan-Kettering Inst Can Research
- Study coordinator: Diamond, Eli Lous
Related research
Other NIH-funded projects on the same topics.
-
Biomarker clues to catch pancreatic cancer early in cysts
A study from UC San Diego is testing blood and cyst-fluid markers to help tell high-risk pancreatic cysts from low-risk ones so that people with pancreatic cysts can get the right care sooner.
-
Myeloproliferative Neoplasm Research Consortium
A large research collaboration across multiple centers aims to improve survival for patients with myelofibrosis and related myeloproliferative neoplasms through coordinated laboratory, translational, and clinical work.
-
Understanding how different CALR mutations drive certain blood cancers
This grant explores how two CALR mutation types cause myeloproliferative neoplasms and could lead to better treatments for people with these blood cancers.
-
Cell Competition in Myeloproliferative Neoplasms
This NIH grant explores how healthy and mutant blood stem cells interact in certain blood cancers to understand why some patients progress and how future therapies might help.
-
Targeting ERK’s brake pedals to slow cancer progression
Aims to block the parts of ERK signaling that speed up cancer progression, by guiding drugs to the substrate-binding domains that act like accelerator pedals in myeloproliferative neoplasms and related cancers.
-
Biomarker work to predict pancreatic IPMN cancer risk
A Duke University researcher is testing biomarkers to tell which pancreatic IPMN cysts are likely to become invasive cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.